Drug intelligence / Profile preview

健脾益肺II号

Development stage: Preclinical
Lead developer: Guangzhou University of Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

健脾益肺II号是一种中药复方制剂，主要用于治疗慢性阻塞性肺疾病（COPD）等以气虚、痰湿为主的呼吸系统疾病。其组方获得国家授权专利，并在质量控制和制备工艺上有创新。药理研究显示，该方能纠正由烟熏和脂多糖诱导的大鼠氧化/抗氧化失衡，减轻气道阻力和胸腔压力，从而保护肺组织免受氧化损伤。这可能是其治疗COPD的主要作用机制之一[1][2]。

Brand names: 健脾益肺II号
Other names: 健脾益肺二号

Beyond the preview

Go deeper on 健脾益肺II号.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 健脾益肺II号.

Explore the full profile